NG-101
HER2‑positive solid tumors
PreclinicalActive
Key Facts
Indication
HER2‑positive solid tumors
Phase
Preclinical
Status
Active
About Nanogen Pharmaceutical Biotechnology
South Korean biotech leveraging nanobody‑based therapeutics for oncology and immunology.
View full company profileTherapeutic Areas
Other HER2‑positive solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| GBC-002 | General Biologicals Corporation | Pre‑clinical |